Clinical trials: in Burkina Faso
Health Education, Health Communication
Evaluation of "C'Est La Vie!" Digital Health Education
The University of California, Los Angeles (UCLA) will lead the online evaluation of four digital health campaigns developed by a non-governmental organization (NGO), Réseau Africain de l'Éducation pour la Santé (RAES), or African…
- Trial name
- NCT07636629
- Testing
- Evaluating how to deliver messages to young people online
- Where
- 3 sites in Burkina Faso, Côte d’Ivoire and 1 more
- Volunteers
- 492 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Typhoid
Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso
This study evaluated the persistence of immunity following primary typhoid conjugate vaccination in early childhood and assessed the immunogenicity and safety of a booster dose administered 5-6 years later.
- Trial name
- NCT07624175
- Testing
- Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM
- Where
- Burkina Faso
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Kathleen Neuzil
Malaria (Plasmodium Falciparum)
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
This is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa.
- Trial name
- BFSPZL2 (NCT07385287)
- Testing
- Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride)
- Where
- Burkina Faso
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Severe Acute Malnutrition, Moderate Acute Malnutrition
Alternative RUTFs for Treatment of Child Wasting
Acute malnutrition is the most life-threatening form of undernutrition. Moderate and severe acute malnutrition (MAM, SAM) are effectively treated with ready-to-use therapeutic foods (RUTFs) but there is a need to lower the cost…
- Conditions
- Severe Acute Malnutrition, Moderate Acute Malnutrition, Wasting
- Trial name
- NCT06912620
- Testing
- Soy-based RUTF, Soy-maize-sorghum-based RUTF, Standard RUTF
- Where
- Burkina Faso
- Volunteers
- 2,269 people
- Sponsor
- International Food Policy Research Institute
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Schistosomiasis
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
The goal of this phase 1b, multicenter, randomized, placebo-controlled, observer-blinded, dose-escalation study is to assess the safety, tolerability, and immunogenicity of a three-dose regimen, spaced four weeks apart, given…
- Trial name
- NCT05762393
- Testing
- rSm-p80 + GLA-SE
- Where
- 2 sites in Burkina Faso, Madagascar
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
HIV/AIDS
Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)
This demonstration project will assess the acceptability and feasibility of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) as part of a comprehensive HIV prevention package in community-based clinics in West…
- Trial name
- CohMSM-PrEP (NCT03459157)
- Testing
- HIV prevention package including PrEP
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 649 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Malaria Falciparum, Malaria Infection
Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a first-in-humans randomized, double-blind, placebo-controlled, age de-escalation Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine…
- Trial name
- NCT06652737
- Testing
- PfSPZ-LARC2 Vaccine
- Where
- Burkina Faso
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
HIV Infection
Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa
The objective of the study is to evaluate the feasibility and interest of a HIV quarterly preventive global care for men who have sex with men (MSM) in sub-Saharan Africa to help reducing HIV incidence in this key population…
- Trial name
- CohMSM (NCT02626286)
- Testing
- HIV quarterly global care
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 885 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Severe Malaria
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
The purpose of this study was to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria.
- Trial name
- NCT04675931
- Testing
- Cipargamin, IV Artesunate, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 254 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Malaria Transmission in Humans and Mosquitoes at the Area of Sabou, Burkina Faso
Background: Malaria is a disease that affects many people in Burkina Faso. It is caused by germs that are spread by mosquito bites. A vaccine that blocks the spread of malaria is important to get rid of the disease.
- Trial name
- NCT04650815
- Where
- 2 sites in Burkina Faso
- Volunteers
- 608 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Malaria, Uncomplicated Malaria
Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX
Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. A new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion…
- Conditions
- Severe Malaria, Uncomplicated Malaria, Asyptomatic Plasmodium Infection
- Trial name
- IMMETASEX (NCT06064591)
- Where
- 3 sites in Belgium, Burkina Faso and 1 more
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria Incidence, Seasonal Malaria Chemoprevention
Leveraging the Seasonal Malaria Chemoprevention Platform to Address Malaria and Malnutrition
In the Sahel, the malaria and malnutrition seasons overlap during the rainy season, from approximately July through October. Malaria transmission increases due to the rain and collection of standing water and malnutrition risk…
- Conditions
- Malaria Incidence, Seasonal Malaria Chemoprevention, Nutrition Assessment, Acute Malnutrition in Childhood
- Trial name
- INSPIRE (NCT06599593)
- Testing
- SQ-LNS, Integrated Nutritional Screening
- Where
- Burkina Faso
- Volunteers
- 438 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Retinoblastoma
Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and…
- Trial name
- GFARB12019 (NCT04425434)
- Testing
- OBSERVATIONAL
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 3,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Burkitt Lymphoma
Recommendations for the Treatment of Children With Burkitt's Lymphoma
This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units…
- Trial name
- GFALMB2019 (NCT04425421)
- Testing
- OBSERVATIONAL
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 1,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Nephroblastoma
Therapeutic Recommendations for Nephroblastoma
The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.
- Trial name
- GFANEPHRO20 (NCT04423484)
- Testing
- Data collection
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 1,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Resting Heart Rate, Blood Glucose Control
Assessing the Effects of Cool Roofs on Indoor Environments and Health
Ambient air temperatures in Asian, Latin American, African, and Pacific climate hotspots have broken record highs in 2024, driven by man-made climate change. Solutions are needed to reduce heat exposure in communities.
- Conditions
- Resting Heart Rate, Blood Glucose Control, Depression, Heat-related Symptoms
- Trial name
- REFLECT (NCT06579950)
- Testing
- Cool roof
- Where
- 5 sites in Burkina Faso, Fiji and 3 more
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Aditi Bunker
Heart Rate, All-day Steps
Assessing the Effect of Cool Roofs on Health Using Smartwatches
Ambient air temperatures in Asian, Latin American, African, and Pacific climate hotspots have broken record highs in 2024. Solutions are needed to build heat resilience in communities and adapt to increasing heat from climate…
- Conditions
- Heart Rate, All-day Steps, Distance Walked, Active Minutes
- Trial name
- REFLECT (NCT06579963)
- Testing
- Cool roof
- Where
- 4 sites in Burkina Faso, India and 2 more
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Aditi Bunker
Plasmodium Falciparum Malaria
Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant
Assessing the safety, immunogenicity and ex-vivo efficacy of two transmission blocking vaccines (Pfs25-IMX313 in Matrix M and Pfs48/45 in Matrix M alone and co-administered) in Burkina Faso, in 18-45 years, 12-17 years and 05-11…
- Trial name
- NCT06549257
- Testing
- Pfs25-IMX313, Pfs48/45
- Where
- Burkina Faso
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Measles Vaccine
Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.
Background: All observational studies and a few randomised controlled trials (RCT) suggest that early measles vaccine (MV), in particular an early two-dose strategy, has a much better effect on overall mortality than later MV.
- Trial name
- NCT01668745
- Testing
- Early measles vaccine
- Where
- Burkina Faso
- Volunteers
- 4,559 people
- Sponsor
- Bandim Health Project